Pre-hospital treatment with crushed versus integral tablets of prasugrel in patients presenting with ST-Segment Elevation Myocardial Infarction—1-year follow-up results of the COMPARE CRUSH trial

Rosanne F. Vogel, Ronak Delewi, Jeroen M. Wilschut, Miguel E. Lemmert, Roberto Diletti, Ria van Vliet, Nancy W. P. L. van der Waarden, Rutger-Jan Nuis, Valeria Paradies, Dimitrios Alexopoulos, Felix Zijlstra, Gilles Montalescot, Dominick J. Angiolillo, Mitchell W. Krucoff, Pieter C. Smits, Nicolas M. van Mieghem, Georgios J. Vlachojannis

Research output: Contribution to JournalComment / Letter to the editorAcademic

Abstract

The present research letter reports the 1-year clinical outcomes of the randomized COMPARE CRUSH trial, which allocated STEMI patients at first medical contact in the ambulance to receive either crushed or integral tablets of prasugrel loading dose. This trial aimed to investigate whether early enhanced antiplatelet effect constituted by the crushed potent oral P2Y12 inhibitor prasugrel could lead to improved early myocardial reperfusion and clinical outcomes.
Original languageEnglish
Pages (from-to)26-30
Number of pages5
JournalAmerican heart journal
Volume252
DOIs
Publication statusPublished - 1 Oct 2022

Cite this